Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Minerva Neurosciences	Rockwell Medical	Catalyst Biosciences	Processa Pharmaceuticals	Galectin Therapeutics
Symbol	NASDAQ:NERV	NASDAQ:RMTI	NASDAQ:CBIO	NASDAQ:PCSA	NASDAQ:GALT
Price Information
Current Price	$2.43	$1.00	$5.00	$9.36	$2.36
52 Week Range	Buy	Buy	Buy	Buy	Buy
MarketRank™
Overall Score	1.6	1.3	1.5	1.2	1.4
Analysis Score	3.3	3.5	3.5	0.0	3.5
Community Score	2.8	2.4	2.6	5.0	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	1.7	0.0	0.8	0.8	0.8
Earnings & Valuation Score	0.0	0.6	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Buy	Buy
Consensus Price Target	$6.75	$5.50	$17.00	N/A	$12.00
% Upside from Price Target	177.78% upside	450.00% upside	240.00% upside	N/A	408.47% upside
Trade Information
Market Cap	$103.81 million	$93.59 million	$156.66 million	$145.29 million	$134.89 million
Beta	1.49	1.11	2.07	-0.06	2.04
Average Volume	607,803	2,049,297	472,228	75,337	1,496,147
Sales & Book Value
Annual Revenue	N/A	$61.30 million	$10,000.00	N/A	N/A
Price / Sales	N/A	1.53	15,665.50	N/A	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$0.71 per share	$0.32 per share	$5.68 per share	$1.46 per share	$0.76 per share
Price / Book	N/A	3.13	0.88	N/A	N/A
Profitability
Net Income	$-72,180,000.00	$-34,130,000.00	$-55,180,000.00	$-3,360,000.00	$-13,290,000.00
EPS	($1.85)	($0.56)	($4.60)	N/A	($0.39)
Trailing P/E Ratio	N/A	N/A	N/A	0.00	N/A
Forward P/E Ratio	N/A	N/A	N/A	∞	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	N/A	-47.23%	N/A	N/A	N/A
Return on Equity (ROE)	-51.19%	-117.67%	-55.23%	-79.69%	-56.13%
Return on Assets (ROA)	-29.75%	-46.33%	-45.82%	-53.85%	-49.42%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	N/A	0.50%	N/A	0.01%	N/A
Current Ratio	6.49%	6.13%	6.42%	0.14%	13.62%
Quick Ratio	6.49%	5.83%	6.42%	0.14%	13.62%
Ownership Information
Institutional Ownership Percentage	66.28%	26.72%	63.81%	N/A	17.58%
Insider Ownership Percentage	12.00%	4.70%	4.00%	54.60%	40.70%
Miscellaneous
Employees	11	300	34	14	6
Shares Outstanding	42.72 million	93.59 million	31.33 million	15.52 million	57.16 million
Next Earnings Date	5/3/2021 (Estimated)	5/10/2021 (Estimated)	5/10/2021 (Estimated)	5/21/2021 (Estimated)	5/10/2021 (Estimated)
Optionable	Optionable	Optionable	Optionable	Not Optionable	Optionable

Source	Headline
	What's Going On With GALT Stock And TV Stock Today? benzinga.com - April 14 at 3:58 PM
	Galectin Therapeutics Stock Is Trading Higher After Belapectin-Pembrolizumab Combo Study Shows Enhanced Tumor Response finance.yahoo.com - April 14 at 3:58 PM
	Galectin Gains on Product News baystreet.ca - April 14 at 10:58 AM
	Galectin Therapeutics (GALT) Stock Climbs On Data Publication cnafinance.com - April 14 at 10:58 AM
	Journal for ImmunoTherapy of Cancer Publishes... benzinga.com - April 14 at 12:56 AM
	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, apnews.com - April 14 at 12:56 AM
	Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy finance.yahoo.com - April 13 at 7:55 PM
	-$0.17 EPS Expected for Galectin Therapeutics Inc. (NASDAQ:GALT) This Quarter americanbankingnews.com - April 8 at 4:22 AM
	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians ... apnews.com - April 7 at 1:00 AM
	Investors Buy High Volume of Galectin Therapeutics Call Options (NASDAQ:GALT) americanbankingnews.com - April 7 at 12:38 AM
	Insider Buying: Galectin Therapeutics Inc. (NASDAQ:GALT) Director Buys 5,000 Shares of Stock americanbankingnews.com - April 6 at 10:42 AM
	Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study finance.yahoo.com - April 6 at 9:28 AM
	Fund L.P. 10X Sells 10,000 Shares of Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock americanbankingnews.com - April 5 at 5:18 PM
	Galectin Therapeutics (NASDAQ:GALT) Announces Quarterly Earnings Results americanbankingnews.com - April 1 at 6:48 PM
	Galectin Therapeutics (NASDAQ:GALT) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS americanbankingnews.com - April 1 at 8:34 AM
	Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update finance.yahoo.com - March 31 at 1:01 PM
	Analysts Anticipate Galectin Therapeutics, Inc. (NASDAQ:GALT) Will Announce Earnings of -$0.16 Per Share americanbankingnews.com - March 22 at 12:14 AM
	OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy finance.yahoo.com - March 8 at 11:34 AM
	Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - March 4 at 12:28 PM
	Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference finance.yahoo.com - March 4 at 12:28 PM
	What Kind Of Investors Own Most Of Galectin Therapeutics, Inc. (NASDAQ:GALT)? finance.yahoo.com - January 31 at 9:00 AM
	Insider Sells Galectin Therapeutics Stock finance.yahoo.com - January 19 at 6:00 PM
	GALT Jan 2021 10.000 put uk.finance.yahoo.com - January 1 at 11:21 PM
	Galectin Therapeutics Inc. Common Stock (GALT) nasdaq.com - December 18 at 9:18 PM
	Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020 finance.yahoo.com - December 11 at 8:19 AM

Date	Company	Brokerage	Action
9/11/2020	Minerva Neurosciences	William Blair	Reiterated Rating
7/2/2020	Minerva Neurosciences	HC Wainwright	Reiterated Rating
7/1/2020	Minerva Neurosciences	JMP Securities	Reiterated Rating
6/1/2020	Minerva Neurosciences	BTIG Research	Lower Price Target
5/29/2020	Minerva Neurosciences	Jefferies Financial Group	Downgrade
12/2/2019	Minerva Neurosciences	Chardan Capital	Reiterated Rating
8/3/2018	Minerva Neurosciences	Citigroup	Boost Price Target
11/11/2019	Rockwell Medical	Piper Jaffray Companies	Lower Price Target
6/24/2019	Rockwell Medical	Cantor Fitzgerald	Initiated Coverage
6/19/2019	Rockwell Medical	Ifs Securities	Downgrade
3/4/2021	Catalyst Biosciences	Raymond James	Set Price Target
2/10/2021	Catalyst Biosciences	Piper Sandler	Initiated Coverage
11/5/2020	Catalyst Biosciences	Lifesci Capital	Reiterated Rating
8/6/2020	Catalyst Biosciences	Ci Capital	Reiterated Rating
1/4/2019	Catalyst Biosciences	CIBC	Initiated Coverage
1/4/2019	Catalyst Biosciences	Oppenheimer	Initiated Coverage
6/21/2018	Catalyst Biosciences	B. Riley	Downgrade
12/8/2020	Processa Pharmaceuticals	Benchmark	Initiated Coverage
10/28/2020	Processa Pharmaceuticals	Craig Hallum	Initiated Coverage

(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources